Union Minister for Chemicals and Fertilizers, Shri D.V. Sadananda Gowda launched a mobile application “Janaushadhi Sugam” which will enable people to search Janaushadhi generic medicines and the stores at the tip of their fingers.
Pharma News
Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
-
-
- Read more about WHO revises recommendations on hormonal contraceptive use for women at high HIV risk
The World Health Organization (WHO) has revised its guidance on contraceptive use to reflect new evidence that women at high risk of HIV can use any form of reversible contraception, including progestogen-only injectables, implants and intrauterine devices (IUDs), without an increased risk of HIV infection.
-
The Central TB Division of the Health Ministry has signed a Memorandum of Understanding (MoU) with Wadhwani Institute for Artificial Intelligence to explore the application of cutting-edge Artificial Intelligence technology in its fight against TB. The MoU was signed by Shri Vikas Sheel, Joint Secretary (HFW) and Dr P Anandan, CEO ( Wadhwani AI).
-
As the Ebola outbreak in the Democratic Republic of the Congo reaches 3000 cases, WHO calls for the full force of all partners to respond and increase their presence in the field to stop Ebola and to address one of the largest and most complex humanitarian crises in the world.
-
A WHO expert advisory committee has approved the first phase of a new global registry to track research on human genome editing. The 18-member committee also announced an online consultation on the governance of genome editing.
-
The Union Cabinet, chaired by the Prime Minister Shri Narendra Modi has approved signing of agreement between the National Medicinal Plants Board, Ministry of AYUSH of the Republic of India and the National Institute of Health of the Ministry of Health of the Republic of Peru on Cooperation in the field of Medicinal Plants.
-
Misinformation about vaccines is as contagious and dangerous as the diseases it helps to spread. The World Health Organization (WHO) welcomes Pinterest’s leadership in protecting public health by only providing evidence-based information about vaccines to its users. We hope to see other social media platforms around the world following Pinterest’s lead.
-
The U.S. Food and Drug Administration approved Nourianz (istradefylline) tablets as an add-on treatment to levodopa carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes. An off episode is a time when a patient’s medications are not working well, causing an increase in PD symptoms, such as tremor and difficulty walking.
According to the National Institutes of Health, PD is the second-most common neurodegenerative disorder in the U.S. after Alzheimer’s disease. An estimated 50,000 Americans are diagnosed with PD each year, and about one million Americans have the condition. The neurological disorder typically occurs in people over age 60, although it can occur earlier. It happens when cells in the brain, which produce a chemical called dopamine, become impaired or die. Dopamine helps transmit signals between the areas of the brain that produce smooth, purposeful movements – such as eating, writing, and shaving. Early symptoms of the disease are subtle and typically worsen gradually; however, the disease progresses more quickly in some people than in others.
The effectiveness of Nourianz in treating "off" episodes in patients with PD who are already being treated with levodopa/carbidopa was shown in four 12-week placebo-controlled clinical studies that included a total of 1,143 participants. In all four studies, patients treated with Nourianz experienced a statistically significant decrease from baseline in daily “off” time compared to patients receiving a placebo.
The most common adverse reactions observed in patients taking Nourianz were involuntary muscle movement (dyskinesia), dizziness, constipation, nausea, hallucination and sleeplessness (insomnia). Patients should be monitored for development of dyskinesia or exacerbation of existing dyskinesia. If hallucinations, psychotic behavior, or impulsive/compulsive behavior occurs, a dosage reduction or stoppage of Nourianz should be considered. Use of Nourianz during pregnancy is not recommended. Women of childbearing potential should be advised to use contraception during treatment.
-
EMA has recommended new measures to prevent serious and potentially fatal errors with the dosing of methotrexate for treating inflammatory diseases such as rheumatoid arthritis, psoriasis and Crohn’s disease. The recommendations result from a review of reports that patients are using methotrexate incorrectly despite previous measures to prevent errors.
-
The World Health Organization (WHO) today calls for a further assessment of microplastics in the environment and their potential impacts on human health, following the release of an analysis of current research related to microplastics in drinking-water. The Organization also calls for a reduction in plastic pollution to benefit the environment and reduce human exposure.
RECOMMENDED POSTS
Subscribe with us
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
